Last updated on February 2018

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Malignant neoplasm of prostate
  • Age: - 100 Years
  • Gender: Male

Inclusion Criteria:

  • patients with prostate cancer post radical radiation therapy and LHRH agonist treated in PCSIV clinical trial
  • biochemical failure (PSA nadir + 2) or minimum follow-up of 3 years post completion of hormonal therapy
  • high risk group
    1. gleason score 8-10
    2. PSA 20 ng/ml
    3. T3 or T4

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.